Cediranib and Olaparib Combination Compared with Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung Min Lee, Mark F. Brady, Austin Miller, Richard G. Moore, Helen MacKay, Leah McNally, Jayanthi Lea, Daron Street, Stephanie Lheureux, Megan E. McDonald, Linda R. Duska, Guilherme Cantuaria, Juraj Kavecansky, Charles A. Leath, Matthew Powell, Mark G. Cadungog, Peter G. Rose, Yong Man Kim, Helen Q. Huang, Michèle ProvencherLari B. Wenzel, Michael A. Bookman, Elise C. Kohn, Angeles Alvarez Secord
Dive into the research topics of 'Cediranib and Olaparib Combination Compared with Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005'. Together they form a unique fingerprint.